Biontech announces first quarter 2023 financial results and corporate update

Covid-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations biontech and partner oncoc4 plan to start a phase 3 clinical trial evaluating anti-ctla-4 antibody bnt316 (onc-392) as monotherapy in nsclc patients who progress after pd-1/pd-l1 treatment added new class of precision therapeutics to clinical-stage oncology portfolio, with next-generation antibody-drug conjugate (adc) candidates presenting clinical data on antibody candidate bnt316 (onc-392), adc candidate bnt323 (db-1303) and car-t candidate bnt211 at the 2023 american society of clinical oncology annual meeting broadened clinical-stage infectious disease vaccine pipeline with the start of a first-in-human clinical trial for the first mrna-based tuberculosis vaccine candidates reiterates biontech covid-19 vaccine revenue guidance of approximately €5 billion in 2023 first quarter1 revenues of €1.3 billion2, net profit of €0.5 billion and fully diluted earnings per share of €2.05 ($2.203) conference call and webcast scheduled for may 8, 2023, at 8:00 am edt (2:00 pm cest) mainz, germany, may 8, 2023 (globe newswire) --  biontech se (nasdaq: bntx, “biontech” or the “company”) today reported financial results for the three months ended march 31, 2023, and provided an update on its corporate progress. “in the first quarter of 2023, we expanded our toolkit of cutting-edge technologies to new modalities and added a novel immune checkpoint inhibitor candidate targeting ctla-4 and two investigational antibody-drug conjugates to our arsenal against cancer.
BNTX Ratings Summary
BNTX Quant Ranking